It often feels as though years working in the cannabis industry are like "dog years," since so much has happened in such a comparably short period of time. It was barely 2 1/2 years ago, after all, on Aug. 15, 2018, that Constellation Brands, Inc., the Fortune 500 beer, wine and spirits company, announced that it had agreed to invest $5 billion CAD (approximately USD $4 billion) in Canopy Growth Corp. kicking off a euphoric period of cannabis transactions. A few weeks later in October 2018, MedMen Enterprises announced its agreement to purchase PharmaCann at a $682.0 million valuation, by far the largest acquisition to date of a U.S.-based cannabis company. Announcements of other significant transaction agreements quickly followed, including the public listings of several large U.S.-based MSOs (multistate operators) on the Canadian Securities Exchange (CSE) and Altria's USD $1.8 billion investment in Cronos in December 2018. In April 2019, a number of record-breaking M&A deals were announced in rapid succession, including Cresco's USD $823.5 million acquisition of Origin House, Harvest's planned USD $850 million acquisition of Verano, Curaleaf's USD $948.8 million acquisition of Cura Partners, and Acreage's plan of arrangement with Canopy giving Canopy the option (and the requirement upon federal cannabis legalization) to purchase Acreage in a transaction then valued at $3.4 billion.